Myocet Liposomal (Doxorubicin Hydrochloride)

Doxorubicin Hydrochloride, the active ingredient in Myocet Liposomal, is an anthracycline antibiotic presented as a liposomal injection for intravenous use. It is employed in the treatment of certain advanced solid tumours, notably metastatic breast cancer and ovarian cancer.

GNH USA supplies Myocet Liposomal as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Myocet Liposomal, an anthracycline used in oncology, is indicated for the following conditions:

- Metastatic breast cancer: improves disease control in patients with advanced disease. - Ovarian cancer: used in combination regimens for recurrent or refractory disease.

Myocet Liposomal may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Alopecia: reversible hair loss. - Fatigue: generalised tiredness. - Myelosuppression: reduced blood cell counts. - Mucositis: inflammation of the mouth lining.

Serious or Rare Side Effects: - Cardiotoxicity: potential for reduced heart function. - Severe neutropenia: heightened infection risk. - Thrombocytopenia: increased bleeding tendency. - Secondary leukemia: rare but serious long‑term risk. - Pulmonary toxicity: rare lung inflammation.

Before initiating therapy, several safety considerations are recommended.

- Cardiac monitoring: baseline and periodic assessment of left ventricular ejection fraction. - Dose adjustments: modify dosing in renal or hepatic impairment as advised. - Avoid concurrent cardiotoxic agents: limit use with other anthracyclines or trastuzumab. - Monitor blood counts: regular complete blood count to detect myelosuppression. - Pregnancy and lactation: contraindicated unless benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myocet Liposomal can interact with several other medicines.

Major Interactions (Avoid): - Concurrent anthracyclines: additive cardiotoxicity. - Trastuzumab co‑administration: heightened risk of cardiac dysfunction.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors: may increase plasma concentrations of doxorubicin. - Radiation therapy: potential for enhanced tissue damage. - Anticoagulants: increased bleeding tendency.